BioSpace News Archive

Podcast

BridgeBio’s ATTR-CM Approval, Cassava’s Alzheimer’s Failure, Trump’s Cabinet Picks, More

BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for Amvuttra in the indication; Cassava’s controversial Alzheimer’s drug flunks Phase III; Amgen’s MariTide fails to impress investors, Donald Trump’s controversial nominations continue.

November 27, 2024

·

1 min read

·

Heather McKenzie

Contemporary art collage. Conceptual design. Making financial strategy. Employees sitting on company graph, creating analytics. Way to financial growth. Concept of business, brainstorming, team

Business

The Biggest Pharma Share Moves of the Year So Far

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share price. Other companies have not been so lucky.

November 27, 2024

·

9 min read

·

Annalee Armstrong

Correct decision chosing - confused man character standing on the crossroads and looking at signpost with three different directions - conceptual vector illustration

Neurodegenerative disease

PTC Scraps ALS Asset Utreloxastat After Mid-Stage Fail, Analysts Look to PKU Opportunity

Despite the “unfortunate” failure, William Blair analysts do not believe that the utreloxastat readout will heavily affect PTC, instead postulating that the upcoming FDA decision on its phenylketonuria candidate sepiapterin will be a stronger driver of the biotech’s stock.

November 27, 2024

·

2 min read

·

Tristan Manalac

Bethesda, Maryland 09/12/2020: View of the main historical building (Building 1) of the National Institutes of Health (NIH) inside Bethesda campus. U.S. Public Health Service seal is seen on top of it

Government

Trump Picks Stanford’s Jay Bhattacharya as NIH Lead

Trump is rounding out his health cabinet with another controversial figure: one of the authors of the Great Barrington Declaration, which advocated for herd immunity through infection during the COVID-19 pandemic.

November 27, 2024

·

2 min read

·

Tristan Manalac

Press Releases

35Pharma Closes Series C Financing to Advance Clinical Pipeline of Activin Inhibitors for Pulmonary Hypertension, Cardiometabolic Disease and Obesity

November 27, 2024

·

2 min read

Press Releases

New Data from a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®